Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine N Bailey

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
World Journal of Surgical Oncology|August 30, 2024
Integrating the melanoma 31-gene expression profile test with clinical and pathologic features can provide personalized precision estimates for sentinel lymph node positivity: an independent performance cohortChase Kriza, Brian Martin, Christine N Bailey, et al.
JCO Precision Oncology|September 30, 2024
Reply to H. Seibert et alChristine N Bailey, Brian J Martin, Valentina I Petkov
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
CGE25-104: The 31-GEP Identifies Patients With Early-Stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-Specific and Overall MortalityHarrison Nguyen, Christine N Bailey, Brian Martin, et al.
Current Medical Research and Opinion|January 9, 2023
The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter studyMaki Yamamoto, Brenda Sickle-Santanello, Timothy Beard, et al.
Cancers|January 23, 2024
The 31-Gene Expression Profile Test Outperforms AJCC in Stratifying Risk of Recurrence in Patients with Stage I Cutaneous MelanomaSebastian Podlipnik, Brian J Martin, Sonia K Morgan-Linnell, et al.
Cancers|February 25, 2022
Using a 31-Gene Expression Profile Test to Stratify Patients with Stage I-II Cutaneous Melanoma According to Recurrence Risk: Update to a Prospective, Multicenter StudySebastian Podlipnik, Aram Boada, Jose L López-Estebaranz, et al.
Journal of the American Academy of Dermatology|July 10, 2022
Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile testAbel Jarell, Brian R Gastman, Larry D Dillon, et al.
Laryngoscope Investigative Otolaryngology|February 14, 2022
Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinomaSarah T Arron, Ashley Wysong, Mary A Hall, et al.
JCO Precision Oncology|June 29, 2023
31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER CollaborationChristine N Bailey, Brian J Martin, Valentina I Petkov, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
World Journal of Surgical Oncology|August 30, 2024
Integrating the melanoma 31-gene expression profile test with clinical and pathologic features can provide personalized precision estimates for sentinel lymph node positivity: an independent performance cohortChase Kriza, Brian Martin, Christine N Bailey, et al.
JCO Precision Oncology|September 30, 2024
Reply to H. Seibert et alChristine N Bailey, Brian J Martin, Valentina I Petkov
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
CGE25-104: The 31-GEP Identifies Patients With Early-Stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-Specific and Overall MortalityHarrison Nguyen, Christine N Bailey, Brian Martin, et al.
Current Medical Research and Opinion|January 9, 2023
The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter studyMaki Yamamoto, Brenda Sickle-Santanello, Timothy Beard, et al.
Cancers|January 23, 2024
The 31-Gene Expression Profile Test Outperforms AJCC in Stratifying Risk of Recurrence in Patients with Stage I Cutaneous MelanomaSebastian Podlipnik, Brian J Martin, Sonia K Morgan-Linnell, et al.
Cancers|February 25, 2022
Using a 31-Gene Expression Profile Test to Stratify Patients with Stage I-II Cutaneous Melanoma According to Recurrence Risk: Update to a Prospective, Multicenter StudySebastian Podlipnik, Aram Boada, Jose L López-Estebaranz, et al.
Journal of the American Academy of Dermatology|July 10, 2022
Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile testAbel Jarell, Brian R Gastman, Larry D Dillon, et al.
Laryngoscope Investigative Otolaryngology|February 14, 2022
Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinomaSarah T Arron, Ashley Wysong, Mary A Hall, et al.
JCO Precision Oncology|June 29, 2023
31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER CollaborationChristine N Bailey, Brian J Martin, Valentina I Petkov, et al.
Pageof 1